Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at Orange, California and other locations
Dates
study started
completion around
Principal Investigator
by Jennifer Valerin, MD

Description

Summary

This is a Phase 1, FIH, Dose Escalation and Dose Expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) effects, and preliminary antitumor activity of IK-595, a MEK/RAF molecular glue, administered orally as monotherapy in patients with advanced solid tumors with gene alterations in the RAS- MAPK pathway for whom there are no further treatment options known to confer clinical benefit.

Official Title

A First-in-Human (FiH) Study of IK-595, an Oral Dual MEK/RAF Inhibitor, in Patients With RAS-or RAF-altered Advanced Solid Tumors

Details

Keywords

Solid Tumor, Adult, Colorectal Cancer, Pancreatic Cancer, Malignant Melanoma, Ras (Kras or Nras) Gene Mutation, BRAF Gene Mutation, CRAF Gene Mutation, Non-Small Cell Lung Carcinoma, Thyroid Carcinoma, Gliomas, Malignant, IK-595, RAS-MAPK Pathway, MEK Inhibitor, MEK/RAF Inhibitor, Carcinoma, Melanoma, Non-Small-Cell Lung Carcinoma, Thyroid Neoplasms, Glioma

Eligibility

Locations

  • University of California Irvine accepting new patients
    Orange California 92868 United States
  • City of Hope accepting new patients
    Duarte California 91010 United States

Lead Scientist at UC Irvine

  • Jennifer Valerin, MD
    Associate Clinical Professor, Medicine, School of Medicine. Authored (or co-authored) 10 research publications

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Ikena Oncology
ID
NCT06270082
Phase
Phase 1 research study
Study Type
Interventional
Participants
Expecting 150 study participants
Last Updated